The Upper Limb Muscle Spasticity drugs in development market research report provides comprehensive information on the therapeutics under development for Upper Limb Muscle Spasticity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Upper Limb Muscle Spasticity. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Upper Limb Muscle Spasticity and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Upper Limb Muscle Spasticity by 11 companies/universities/institutes. The top development phase for Upper Limb Muscle Spasticity is phase iii with five drugs in that stage. The Upper Limb Muscle Spasticity pipeline has 12 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Upper Limb Muscle Spasticity pipeline products market are: Huons, Viatris and Ipsen.
The key targets in the Upper Limb Muscle Spasticity pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), and Synaptobrevin (Vesicle Associated Membrane Protein or VAMP).
The key mechanisms of action in the Upper Limb Muscle Spasticity pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with eight drugs in Phase III. The Upper Limb Muscle Spasticity pipeline products include five routes of administration with the top ROA being Intramuscular and three key molecule types in the Upper Limb Muscle Spasticity pipeline products market including Protein, and Recombinant Protein.
Upper Limb Muscle Spasticity overview
Spasms or spasticity is a condition in which the stiffening of muscles is seen. Upper limb muscle spasticity is a motor neuron syndrome of the upper extremities. This condition causes voluntary movement impairment following stroke, spinal cord injury, and paralysis. It commonly affects elbows, arms, forearms, wrists and is characterized by muscle stiffness, impaired movement, pain, and reduced ability to relax muscles. It commonly occurs in survivors of TBI and stroke. Based on physical examination and radiographic findings diagnosis is done. Physiotherapy like stretching, and pharmacological management with BoNT-A injection and by electrical stimulation of muscles.
For a complete picture of Upper Limb Muscle Spasticity’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
